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ORIGINAL ARTICLE
Effects of dexmedetomidine on renal tissue after lower limb ischemia
reperfusion injury in streptozotocin induced diabetic rats
Meral Erdal Erbatura, Şaban Cem Sezenb, Aslıhan Cavunt Bayraktarc, Mustafa Arslana, Mustafa Kavutçuc
and Muhammed Enes Aydına
aDepartment of Anesthesiology and Reanimation, Gazi University, Ankara, Turkey; bDepartment of Histology and Embryology, Kırıkkale
University, Kırıkkale, Turkey; cDepartment of Medical Biochemistry, Gazi University, Ankara, Turkey
ABSTRACT
Aim: The aim of this study was to investigate whether dexmedetomidine – administered
before ischemia – has protective effects against lower extremity ischemia reperfusion injury
that induced by clamping and subsequent declamping of infra-renal abdominal aorta in
streptozotocin-induced diabetic rats.
Material and Methods: After obtaining ethical committee approval, four study groups each
containing six rats were created (Control (Group C), diabetes-control (Group DM-C), diabetes
I/R (Group DM-I/R), and diabetes-I/R-dexmedetomidine (Group DM-I/R-D). In diabetes groups,
single-dose (55 mg/kg) streptozotocin was administered intraperitoneally. Rats with a blood
glucose level above 250 mg/dl at the 72nd hour were accepted as diabetic. At the end of
four weeks, laparotomy was performed in all rats. Nothing else was done in Group C and DM-
C. In Group DM-I/R, ischemia reperfusion was produced via two-hour periods of clamping and
subsequent declamping of infra-renal abdominal aorta. In Group DM-I/R-D, 100 μg/kg dex-
medetomidine was administered intraperitoneally 30 minutes before ischemia period. At the
end of reperfusion, period biochemical and histopathological evaluation of renal tissue
specimen were performed.
Results: Thiobarbituric acid reactive substance (TBARS), Superoxide dismutase (SOD), Nitric
oxide synthase (NOS), Catalase (CAT) and Glutathion S transferase (GST) levels were found
significantly higher in Group DM-I/R when compared with Group C and Group DM-C. In the
dexmedetomidine-treated group, TBARS, NOS, CAT, and GST levels were significantly lower
than those measured in the Group D-I/R. In histopathological evaluation, glomerular vacuo-
lization (GV), tubular dilatation (TD), vascular vacuolization and hypertrophy (VVH), tubular
cell degeneration and necrosis (TCDN), tubular hyaline cylinder (THC), leucocyte infiltration
(LI), and tubular cell spillage (TCS) in Group DM-I/R were significantly increased when
compared with the control group. Also, GV, VVH, and THC levels in the dexmedetomidine-
treated group (Group DM-I/R-D) were found significantly decreased when compared with the
Group DM-I/R.
Conclusion: We found that dexmedetomidine − 100 μg/kg intraperitoneally – administered
30 minutes before ischemia in diabetic rats ameliorates lipid peroxidation, oxidative stress,
and I-R-related renal injury. We suggest that dexmedetomidine administration in diabetic rats
before I/R has renoprotective effects.
ARTICLE HISTORY
Received 12 September 2016







diabetes; TBARS; SOD; NOS;
histopathology
Introduction
The sixth edition of Diabetes Atlas by the
International Diabetes Fedaration (UDF) reported 385
million new diagnoses of diabetes mellitus in 2013,
and additionally it is estimated that 592 million new
diagnoses of diabetes mellitus will be determined in
2035 [1]. Besides important morbidity and mortality
rates, diabetes is related to increased financial burden
for both patients and governments [2]. In diabetic
populations, important complications including
hypertension, ischemic heart disease, nephropathy,
and autonomic neuropathy are commonly seen, and
physicians inevitably encounter these risks during sur-
gical- and anesthesia-related procedures. Also, dia-
betic patients are at high risk of microvascular,
cardiovascular complications and early mortality.
Owing to these risk factors, anesthesia care in this
patient group has relatively high burden [3–5].
Additionally, more careful perioperative care is
needed in diabetic patients [6,7].
Ischemic injury occurs when the blood supply to an
area of tissue is cut off. The incidence of ischemic
injury is vast: myocardial infarction; stroke; and other
thrombotic events. Ischemic injury also occurs during
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surgery when blood vessels are cross-clamped, and in
organs for transplant.
Infra-renal abdominal aorta and lower extremity
arteries clamping during surgery result in ischemia
of distal body parts. Unclamping of these vascular
structures after clamping result in reperfusion injury
of local and distant organs/tissues [8].
Perioperative acute kidney injury (AKI) is a conse-
quence of sudden renal function deterioration during
major cardiothoracic, vascular, and transplant surgery.
AKI is related to increased mortality and elongated
hospital stay at a ratio of 60%. Mortality rates are 25
times higher following heart valve surgery.
Additionally, completely recovered patients with an
AKI history are still at high risk of long-term mortality.
Ischemia reperfusion (I/R) injury is the leading factor
for perioperative AKI. Following partial or total depri-
vation of renal blood flow, a restored and rigorous
blood flow leads to post-ischemic renal parenchyma
injury characterized by vascular, tubular and inflam-
matory degeneration [9].
Suspected mechanisms underlying renoprotective
effects of dexmedetomidine (is an agonist of α2-adre-
nergic receptors in certain parts of the brain) include
decreased presynaptic and peripheral – increased in
relation with stress – noradrenaline release. Following
dexmedetomidine administration, ameliorations in
glomerular filtration and renal blood flow have been
shown in previous studies. Dexmedetomidine – admi-
nistered during surgery – decreases plasma catecho-
lamine levels, increases urinary output, and secures
hemodynamic stability [10,11]. In animal studies,
renoprotective effects of α₂-adreno-receptor agonists
have been shown [9,12–15].
In this study, we aimed to investigate whether
dexmedetomidine has protective effects against
lower extremity ischemia reperfusion injury induced
by clamping and subsequent unclamping of infra-
renal abdominal aorta in streptozotocin-induced dia-
betic rats.
Material and methods
After obtaining ethical committee approval, 24 Wistar
albino rats – 200–270 g – were randomly divided into
four groups: Group C; Group DM-C; Group DM-I/R; and
Group DM-I/R-D. Diabetes was induced using
Streptozotocin (Sigma Chemical, St Louis. MO, USA)
at a single dose of 55 mg/kg in citrate buffer (0.1
Molar, pH 4.5). Rats with a blood glucose level –
determined (GlucoDr Super Sensor, Allmedicus,
Korea) from blood samples drawn via tail vein –
above 250 mg/dl is accepted as diabetic. No addi-
tional intervention was done in Group C and Group
DM-C. After a four-week follow-up period [16], lapar-
otomy was performed in all groups detailed below.
General anesthesia induction was done using
intramuscular injection of 100 mg/kg ketamine hydro-
chloride (Ketalar® flakon, Parke-Davis, USA). Rats were
kept under a heat lamp. All procedures were per-
formed in the supine position. After skin asepsis, mid-
line laparotomy was performed. After removing
intestines from the surgical field, the infra-renal
abdominal aorta was explored. The aorta was
clamped using an atraumatic microvascular clamp.
The clamp was removed at the end of 120 minutes
of ischemia, then reperfusion was provided for
another 120 minutes. Ischemia was determined
when distal aorta pulsation disappeared, while reper-
fusion was determined when it reappeared. In the
control group, laparotomy and abdominal aorta dis-
section were applied during the same time period
(240 minutes); however, I/R was not applied in these
groups. In other groups, in order to minimize heat
and fluid loss, intraperitoneal serum physiological was
administered at clamping and declamping periods.
Also, the abdominal incision was covered with wet
gauze. In Group DM-I/R-D, 100 μg/kg dexmedetomi-
dine was administered intraperitoneally 30 minutes
before ischemia period. At the end of reperfusion
period, biochemical and histopathological evaluations
of renal tissue specimen were performed. Rats were
decapitated at the end of experiment.
Histopathological evaluation was performed in the
Kirikkkale University Medical Faculty Histology and
Embryology Department. After routine fixation pro-
cess, specimens were embedded in paraffin blocks,
then tissue sections of 5 μ were mounted on slides
for staining with hematoxylin and eosin (H&E).
Histopathological evaluation under light microscopy
was performed, and findings were scored using a
scoring system by Bostan et al. [17]. Glomerular
vacuolization (GV), tubular dilatation (TD), vascular
vacuolization and hypertrophy (VVH), tubular cell
degeneration and necrosis (TCDN), Bowman space
dilatation (BSD), tubular hyaline cylinder (THC), leuco-
cyte infiltration (LI), and tubular cell spillage (TCS)
were scored using a scoring system: 0: no change;
+1: minimal change; +2: medium; +3: severe.
Biochemical evaluation was performed in the Gazi
University Medical Faculty Medical Biochemistry
Department. Oxidative stress and lipid peroxidation
were evaluated using Thiobarbituric acid reactive sub-
stance (TBARS) levels as Malondialdehyde (MDA) indi-
cators in renal tissue. Also, Catalase (CAT), Glutathione
s transferase (GST), Nitric oxide synthase (NOS) and
Superoxide Dismutase (SOD) activities were
measured.
SOD, CAT, GST, and NOS enzyme analyses were
performed as described by Durak, Aebi, Habig, and
Durak [respectively 18–21]. The SOD activity method
is based on the measurement of absorbance increase
at 560 nm due to reduction of NBT to NBTH2. One unit
of SOD activity was defined as the enzyme protein





























amount causing 50% inhibition in NBTH2 reduction
rate. The CAT activity method is based on the mea-
surement of the absorbance decrease due to H2O2
consumption at 240 nm. The GST activity method is
based on the measurement of absorbance changes at
340 nm due to formation of a GSH-CDNB complex.
The NOS activity method is based on the diazotization
of sulfanilic acid by nitric oxide at acid pH and sub-
sequent coupling to N-(1-napthyl-ethylene diamine),
and absorbance of the sample tube is measured
against the blank tube at 540 nm. In this method,
sodium nitroprusside is used as the chemical
standard.
The TBARS assay was carried out to determine lipid
peroxidation using the thiobarbituric acid method
[22]. TBARS measurements were conducted based
on the reaction of MDA with thiobarbituric acid
(TBA), which form a pink pigment with an absorption
maximum at 532 nm in acid pH, and 1,1,3,3-tetra-
ethoxypropane was used as a standard MDA solution.
All procedures were performed at 4°C throughout
the experiment.
Enzyme activities and TBARS levels were deter-
mined by continuously monitoring and end point
change in absorbance at 25°C with a Shimadzu UV-
1601 spectrophotometer. Results were expressed IU/
mg protein for CAT and NOS, for GST and SOD mIU/
mg protein and U/mg protein respectively. TBARS
results were given nmol/mg protein.
Statistical analysis
We used the SPSS 20.0 packet program for statistical
analysis. A p level < 0.05 determined as statistically
significant. Data were expressed as mean ± standard
deviation. Data were evaluated using Kruskal–Wallis
variance analysis. Significant variables were analysed
using the Mann–Whitney U test with Bonferroni
correction.
Results
In histopathological evaluation, we found
increased GV, TD, VVH, THDN, THS, Lİ, and THD in
Group DM-I/R when compared with Group C. In
Group DM-I/R-D GV, VVH and THS levels were sig-
nificantly lower than those determined in Group
DM-I/R (Figures 1–4, Table 1). In Group DM-I/R,
TBARS, SOD, NOS, CAT, and GST levels were sig-
nificantly higher than those measured in Group C
and Group DM-C. In the Dexmedetomidine-treated
group (Group DM-I/R-D), TBARS, NOS, CAT, and
GST levels were significantly lower than those mea-
sured in DM-I/R (Table 2).
Discussion
Mechanisms responsible for increased inflammatory
response in Type-2 DM and the effects of these
mechanisms on severe renal I/R injury encountered
in Type-DM are unclear. Reactive oxygen products
(ROS) and Nitric Oxide (NO) play an important role
in cellular damage development during I/R processes.
Inflammation significantly contributes to I/R patho-
genesis, in addition to adhesion molecules, cytokines,
and other various cells. Neutrophils are inflammatory
cells that produce high levels of ROS. Diabetic
patients may need renal transplantation secondary
to diabetic nephropathy in their advanced lifetime.
Ischemia reperfusion injury is a dangerous complica-
tion that can be encountered in this period. A short
period of ischemia (30 minutes) may lead to progres-
sive renal injury in diabetics; however, it was shown
that in such circumstance renal failure may be
Figure 1. Renal tissue in control group (Group C).
Pt: Proximal tubule, Dt: Distal tubule, g: glomerular, arrow head: bow-
man space, arrow: dilated tubule, double arrow: macula densa
(H&EX10).
Figure 2. Renal tissue in diabetic control group (Group DM-C).
Pt: Proximal tubule, Dt: Distal tubule, g: glomerular, arrow head: bow-
man space, arrow: dilated tubule Li: Lymphocyte infiltration, vc:
vascular congestion, *: degenerated glomerulus (H&EX10).





























reversed. Renal susceptibility is increased in strepto-
zotocin-induced diabetic rats [23].
Ischemia Reperfusion injury is a well-known trig-
gering factor in AKI. Renal tubules are very susceptible
to ischemia, and prolonged ischemia results in epithe-
lial cellular death in proximal tubular regions. Even
though encountered with prolonged ischemia peri-
ods, normal structure and functions of the kidney
may be recovered. Following I/R injury, pro-inflamma-
tory/inflammatory, injury/recovery processes are all
engaged, and damaged the kidney may be recovered
after I/R injury [24].
A meta-analysis showed that unchanged mortality
rates (50%) related to AKI in the last five decades. AKI
may have occurred in 1% of surgical patients; however,
mortality rates may be as high as 83% in patients
undergoing cardiac surgery. In a retrospective study,
conducted with 2,672 patients undergoing coronary
artery bypass surgery, it was shown that AKI resulted
in a 14-fold increased mortality rate [25]. Also, vascular
interventions, urological procedures, and kidney and
liver transplantations are related to AKI. High-risk
patients – with advanced age, hypertension, diabetes,
decreased cardiac functions, or known renal disease –
undergoing cardiac, vascular or transplantation sur-
geries – which I/R is inevitable – are more susceptible
to AKI occurrence and high mortality rates.
Khajuria et al. [26] indicated decreased renal injury
after dexmedetomidine treatment in rats with I/R
injury. Normal glomerulus structures were seen in
dexmedetomidine-treated rats, while swelling of tub-
ular cells, medullar congestion, and renal cell necrosis
were determined in non-treated animals [26].
Collino et al. [27] showed – in conjunction with
previous studies [28,29] – increased susceptibility to
I/R injury in diabetic rats [28,29].
Figure 3. Renal tissue in diabetic ischemia reperfusion group
(Group DM-I/R).
Pt: Proximal tubule, Dt: Distal tubule, v: vacuolar, Li: lymphoid infil-
tration, g: glomerulus, arrow head: bowman space, arrow: dilated
tubule (H&EX10).
Figure 4. Renal tissue in diabetic ischemia reperfusion trea-
ted with dexmedetomidine group (Group DM-I/R-D).
Pt: Proximal tubule, Dt: Distal tubule, g: glomerulus, v: vacuole, arrow
head: bowman space, arrow: dilated tubule, double arrow: macula
densa (H&EX10).








(n = 6) P**
GST (mIU/mg.protein) 95.77 ± 7.63 276.27 ± 7.46* 937.98 ± 7.83*,& 816.42 ± 7.73*,&,? < 0.0001
CAT (IU/mg protein) 9122.23 ± 1701.14 12516.44 ± 1644.18 18407.05 ± 2438.32*,& 10346.95 ± 1915.87? 0.015
NOS (IU/mg protein) 38.72 ± 11.72 104.19 ± 21.57* 500.76 ± 163.82*,& 175.80 ± 35.73*,? 0.002
TBARS (nmol/mg protein) 7.17 ± 1.19 13.84 ± 1.67* 28.24 ± 4.80*,& 15.42 ± 2.51*,? < 0.0001
SOD (U/mg protein) 9.79 ± 2.29 11.83 ± 2.03 24.09 ± 3.16*,& 16.84 ± 3.80 0.013
*p < 0.05: compared with Group C; &p < 0.05: compared with Group DM-I/R; ?p < 0.05: compared with Group DM-C.
**p significance level with Kruskal-Wallis test p < 0.05.








(n = 6) P**
Glomerular vacuolization (GV) 0.33 ± 0.21 1.00 ± 0.00* 1.33 ± 0.33* 0.67 ± 0.21& 0.029
Tubular dilatation (TD) 0.33 ± 0.21 0.83 ± 0.17 1.83 ± 0.31*,? 1.33 ± 0.21* 0.001
Vascular vacuolization and hypertrophy (VVH) 0.33 ± 0.21 0.83 ± 0.31 1.33 ± 0.66* 0.67 ± 0.21& 0.042
Tubular cell degeneration and necrosis (TCDN) 0.33 ± 0.21 0.83 ± 0.17* 1.00 ± 0.00* 0.83 ± 0.17* 0.040
Bowman space dilatation (BSD) 0.00 ± 0.00 0.33 ± 0.21 0.67 ± 0.21 0.33 ± 0.21 0.117
Tubular hyaline cylinders (THC) 0.17 ± 0.17 0.17 ± 0.17 1.33 ± 0.21*,? 0.67 ± 0.21& 0.001
Lymphocyte infiltration (Lİ) 0.33 ± 0.21 0.67 ± 0.21 1.33 ± 0.21*,? 1.00 ± 0.00* 0.006
Tubular cell spillage (TCS) 0.50 ± 0.22 1.00 ± 0.00* 1.00 ± 0.00* 1.00 ± 0.00* 0.010
*p < 0.05: compared with Group C; &p < 0.05: compared with Group DM-I/R; ?p < 0.05: compared with Group DM-C.
**p significance level with Kruskal-Wallis test p < 0.05.





























Malondialdehyde is an end product of lipid perox-
idation and is accepted as a marker of cell wall per-
oxidation. Plasma and tissue levels of MDA are
accepted as good markers of systemic response fol-
lowing I/R and oxidative stress [30].
Several enzymes have intracellular antioxidant
functions against I/R-induced oxidative stress. High
activity levels of such enzymes are accepted as mar-
kers of inflammation. Catalase (CAT) catalases degre-
dation of hydrogen peroxide and high blood levels of
CAT indicate antioxidant effectiveness [31].
Several studies indicated protective effects of dex-
medetomidine against I/R injury in different organs,
such as lung, heart, brain, and kidney, through its anti-
inflammatory and antioxidant properties [9,32–36].
Kucuk et al. [37] showed increased MDA and SOD
levels decreased CAT activity in hepatic I/R group of
rats. On the other hand, dexmedetomidine adminis-
tration in this experiment resulted in normalization of
MDA and SOD levels. However, they couldn’t find any
change in GST levels. The authors concluded that
dexmedetomidine prevented lipid peroxidation fol-
lowing hepatic I/R injury.
There is no clear recommendation regarding dexme-
detomidine dose range in order to determine effective-
ness of the agent in experimental I/R or inflammatory
response models. Hanci et al. [38] used dexmedetomi-
dine at a dose of 10 μg/kg in testicular I/R model in rats.
Bektaş et al. [39] found higher MDA and NO levels in the
I/R group when compared with those measured in the
control group, I/R + 50 μg/kg dexmedetomidine group
and I/R + 100 μg/kg dexmedetomidine group. Also,
they found lower MDA levels in rats treated with
100 μg/kg dexmedetomidine when compared with
the 50 μg/kg dexmedetomidine-treated group.
However, NO levels were similar in the two dexmede-
tomidine treated groups.
Cakir et al. [40] showed extensive cortical damage
and increased interstitial bleeding in the I/R group
when compared with the control group. They found
decreased tubular damage in the 10 μg/kg dexmede-
tomidine treated group when compared with other
study groups. Interestingly, they found similar histo-
logical findings between the control group and the
dexmedetomidine 100 μg/kg treated group. These
results indicate that 100 μg/kg dexmedetomidine
administration is more effective in recovery of renal
I/R injury.
Göksedef et al. [41] conducted a randomized, dou-
ble–blinded, and placebo-controlled study in 87
patients undergoing coronary artery bypass surgery.
They compared renal effects of placebo and low-dose
intravenous dexmedetomidine. They reported
unchanged renal functions secondary to dexmedeto-
midine administration, and they supposed that a low
dose of the agent that was used in the study may
result in such a consequence. In our study, we used
the maximal safe dose of dexmedetomidine – 100 μg/
kg [42,43] –reported in the literature.
Gonullu et al. showed that the preconditioning or
postconditioning with the administration of dexme-
detomidine could both reduce the renal IRI histomor-
phologically, as the renal histopathological score in
the IRI group was significantly higher than the groups
with dexmedetomidine [44].
Liu et al. showed that before ischemia administration
of dexmedetomidine long term protective effect against
renal IRI through the alleviation of inflammation [45].
In our study, we used a model representing dia-
betic patient group – that may be encountered with
high ARI – and a cardiac, vascular surgical procedure
that inevitably consists I/R. Diabetes was induced
using streptozotocin, and rats were housed for
one month in order to determine chronic effects of
diabetes. Following lower extremity I/R, protective
effects of dexmedetomidine were investigated. We
found that 100 μg/kg dexmedetomidine administered
30 minutes before ischemia resulted in decreased
lipid peroxidation and oxidative stress, and amelio-
rated histopathological findings of renal injury. In
conclusion, we suggest that dexmedetomidine
administration before I/R has renoprotective effects.
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